The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | Treating patients with AML who are ineligible for intensive chemotherapy
Pinkal Desai, MD, MPH, Weill Cornell Medicine, New York, NY, notes that for patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy, the principal aim should be to improve their status, allowing them to proceed to transplant and improve their survival. Dr Desai explains how hypomethylating agents (HMAs) and venetoclax make up the backbone of lower-intensity therapy, with additions of other agents such as gilteritinib targeting specific mutations. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
